The FDA has approved Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii) combined with tislelizumab and chemotherapy for first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA). This approval covers all HER2+ patients regardless of PD-L1 status and is based on the Phase 3 HERIZON-GEA-01 trial showing a median overall survival of 26.4 months, the longest reported in this setting. The new regimen offers a significant survival benefit and establishes a new standard of care for HER2+ advanced GEA, a cancer with poor prognosis and limited treatment options. Jazz Pharmaceuticals will host an investor webcast to discuss the approval and ongoing development plans.
Nvidia reported a strong Q2 with $96.2 billion in revenue, marking a 106% increase and a return to triple-digit growth. The company faces supply chain constraints in memory, advanced packaging, and power components. CEO Jensen Huang highlighted that ...
Nvidia reported one of the largest quarterly profits in corporate history, with revenue of $96.2 billion and net income of $59.7 billion, driven by strong growth in its Data Center segment. Wealth manager Ross Gerber believes the stock is still under...
Certain high-yield dividend stocks like BDCs, REITs, and midstream partnerships pay ordinary income dividends that are taxed heavily in taxable accounts. Holding these stocks in a Roth IRA allows investors to receive all dividend income tax-free, pro...
Covered-call ETFs offering 8%+ yields generate mostly non-qualified income taxed at ordinary rates in taxable accounts, reducing net returns. Holding four specific ETFs—SPYI, JEPI, JEPQ, and DIVO—in a Roth IRA shields investors from these taxes, pres...
Best Buy reported better-than-expected fiscal Q2 results with 4.1% comparable sales growth and raised its full-year revenue guidance to $42.3-$42.8 billion from $41.2-$42.1 billion. Adjusted earnings per share guidance also increased to $6.70-$6.90 f...
